Hyderabad/IBNS: ISSAR Pharmaceuticals, a leading iIndian pharma company specialising in peptide technology and peptide drug innovation, announced they will license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent.
According to the company, the potential collaboration will help it to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.
The company’s founder and chairman, Ramakrishna Reddy Isanaka said, “We take pride in being India’s first ever company to conduct phase-1 clinical trials, and launch the first ever indigenous peptide drug, Melgain in market for the treatment of Vitiligo in 2004.”
ISSAR Pharmaceuticals uses solid-phase peptide synthesis as the technology of choice, and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration.
ISSAR has also developed their second New Chemical Entity called Xylentra, which, according to the company, is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.
ISSAR’s FDA - compliant state-of-the-art peptide manufacturing facility of 62,000 sq. ft., is located in Hyderabad’s famous business district, Genome Valley.